Khandan Keyomarsi

14.0k citations

158 papers · 10.7k indexed · 4 hit papers · h-index 51

Molecular Biology top 0.5%
Oncology top 0.2%
Cancer Research top 0.5%
Cell Biology top 0.5%
Pulmonary and Respiratory Medicine top 1%

Co-authors: Arthur B. Pardee Timothy M. Pawlik Kelly K. Hunt Thaddeus W Herliczek J. Wade Harper Michael Lowe Stephen J. Elledge Saïd Akli
Topics: Cancer-related Molecular Pathways (89 papers)Advanced Breast Cancer Therapies (43 papers)Microtubule and mitosis dynamics (33 papers)
Cited by: Oncology Cancer Research Cell Biology
Journals: Science New England Journal of Medicine Proceedings of the National Academy of Sciences
Partner nations: United States United Kingdom France

In The Last Decade

Khandan Keyomarsi

155 papers receiving 10.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of cyclin-dependent kinases by p21.

1995 855 citations Khandan Keyomarsi et al. profile →
Role of cell cycle in mediating sensitivity to radiotherapy

2004 829 citations Khandan Keyomarsi et al. profile →
Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCF ^Fbw7 Ubiquitin Ligase

2001 649 citations Khandan Keyomarsi et al. profile →
Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance

2024 65 citations Khandan Keyomarsi et al. profile →

Peers

Countries citing papers authored by Khandan Keyomarsi

Since Specialization

Citations

This map shows the geographic impact of Khandan Keyomarsi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khandan Keyomarsi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khandan Keyomarsi more than expected).

Fields of papers citing papers by Khandan Keyomarsi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Khandan Keyomarsi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khandan Keyomarsi. The network helps show where Khandan Keyomarsi may publish in the future.

Co-authorship network of co-authors of Khandan Keyomarsi

This figure shows the co-authorship network connecting the top 25 collaborators of Khandan Keyomarsi. A scholar is included among the top collaborators of Khandan Keyomarsi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Khandan Keyomarsi. Khandan Keyomarsi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract PO1-18-05: Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4/6 inhibitor-resistant breast cancer 2024 ·Cancer Research ·Linjie Luo,Juliana Navarro-Yepes,(unknown),Tuyen Bui,Nicole M. Kettner,Debu Tripathy,(unknown),L. Kerrie,Khandan Keyomarsi	1
2	Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers 2023 ·Cancer Research ·Juliana Navarro-Yepes,Nicole M. Kettner,Xiayu Rao,(unknown),Tuyen Bui,Hannah F. Wingate,Akshara Singareeka Raghavendra,(unknown),Jing Wang,Ayşegül A. Şahin,Funda Meric‐Bernstam,Kelly K. Hunt,Senthil Damodaran,Debu Tripathy,Khandan Keyomarsi	24
3	Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition 2018 ·Clinical Cancer Research ·Xian Chen,(unknown),Angela Alexander,Yufeng Jiang,Cansu Karakaş,Kenneth R. Hess,Jason P.W. Carey,Tuyen Bui,Smruthi Vijayaraghavan,Kurt W. Evans,Min Yi,(unknown),Kwok‐Leung Cheung,Ian O. Ellis,Siqing Fu,Funda Meric‐Bernstam,Kelly K. Hunt,Khandan Keyomarsi	78
4	Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer 2017 ·Cancer Research ·Jason P.W. Carey,Cansu Karakaş,Tuyen Bui,Xian Chen,Smruthi Vijayaraghavan,Yang Zhao,Jing Wang,Keith Mikule,Jennifer K. Litton,Kelly K. Hunt,Khandan Keyomarsi	103
5	Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer 2017 ·Clinical Cancer Research ·Iman Doostan,Cansu Karakaş,(unknown),(unknown),Matthew J. Ellis,John A. Olson,Vera J. Suman,Kelly K. Hunt,Stacy Moulder,Khandan Keyomarsi	35
6	CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest 2017 ·Molecular Cancer Therapeutics ·Ashleigh M. Francis,Angela Alexander,Yanna Liu,Smruthi Vijayaraghavan,(unknown),Dong Yang,Tuyen Bui,Neeta Somaiah,Vinod Ravi,Khandan Keyomarsi,Kelly K. Hunt	41
7	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer 2016 ·Clinical Cancer Research ·Kelly K. Hunt,Cansu Karakaş,Min Jin Ha,Anna Biernacka,Min Yi,Ayşegül A. Şahin,(unknown),Gabriel N. Hortobágyi,Melissa L. Bondy,Patricia A. Thompson,Kwok‐Leung Cheung,Ian O. Ellis,Sarah Bacus,W. Fraser Symmans,Kim‐Anh Do,Khandan Keyomarsi	49
8	Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells 2016 ·Cancer Research ·(unknown),Iman Doostan,Cansu Karakaş,Tuyen Bui,Zhiyong Ding,Gordon B. Mills,Kelly K. Hunt,Khandan Keyomarsi	75
9	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers 2016 ·Molecular Cancer Research ·Kavitha Balaji,Smruthi Vijayaraghavan,Lixia Diao,Pan Tong,You-Hong Fan,Jason P.W. Carey,Tuyen Bui,(unknown),John V. Heymach,Kelly K. Hunt,Jing Wang,Lauren A. Byers,Khandan Keyomarsi	70
10	Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer 2016 ·Molecular Cancer Therapeutics ·(unknown),Xian Chen,Tuyen Bui,Yufeng Jiang,Dong Yang,Smruthi Vijayaraghavan,Mark J. McArthur,Kelly K. Hunt,Khandan Keyomarsi	51
11	Hbo1 Is a Cyclin E/CDK2 Substrate That Enriches Breast Cancer Stem-like Cells 2013 ·Cancer Research ·MyLinh Duong,Saïd Akli,(unknown),Anna Biernacka,Bisrat G. Debeb,Min Yi,Kelly K. Hunt,Khandan Keyomarsi	38
12	The Neutrophil Elastase Inhibitor Elafin Triggers Rb-Mediated Growth Arrest and Caspase-Dependent Apoptosis in Breast Cancer 2010 ·Cancer Research ·(unknown),Kelly K. Hunt,Khandan Keyomarsi	28
13	Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors 2010 ·Clinical Cancer Research ·Saïd Akli,Tuyen Bui,Hannah F. Wingate,Anna Biernacka,Stacy Moulder,Susan L. Tucker,Kelly K. Hunt,Khandan Keyomarsi	41
14	Cyclin E Deregulation Impairs Mitotic Progression through Premature Activation of Cdc25C 2010 ·Cancer Research ·Rozita Bagheri‐Yarmand,(unknown),Anna Biernacka,Tuyen Bui,Khandan Keyomarsi	31
15	Low Molecular Weight Cyclin E Overexpression Shortens Mitosis, Leading to Chromosome Missegregation and Centrosome Amplification 2010 ·Cancer Research ·Rozita Bagheri‐Yarmand,Anna Biernacka,Kelly K. Hunt,Khandan Keyomarsi	45
16	Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer 2009 ·Clinical Cancer Research ·Roshan Agarwal,(unknown),Simen Myhre,Mark Carey,Ju‐Seog Lee,Jens Overgaard,Jan Alsner,Katherine Stemke‐Hale,Aňa Lluch,Richard M. Neve,Wen Lin Kuo,Thérese Sørlie,Ayşegül A. Şahin,Vicente Valero,Khandan Keyomarsi,Joe W. Gray,Anne‐Lise Børresen‐Dale,Gordon B. Mills,Bryan T. Hennessy	111
17	Altered Subcellular Localization of Tumor-Specific Cyclin E Isoforms Affects Cyclin-Dependent Kinase 2 Complex Formation and Proteasomal Regulation 2009 ·Cancer Research ·Nikkí A. Delk,Kelly K. Hunt,Khandan Keyomarsi	36
18	Overexpression of the Low Molecular Weight Cyclin E in Transgenic Mice Induces Metastatic Mammary Carcinomas through the Disruption of the ARF-p53 Pathway 2007 ·Cancer Research ·Saïd Akli,Carolyn S. Van Pelt,Tuyen Bui,Asha S. Multani,Sandy Chang,D. Gale Johnson,Susan L. Tucker,Khandan Keyomarsi	61
19	Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome 2006 ·Cancer Research ·Ekem T. Efuet,Khandan Keyomarsi	43
20	Tumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast Cancer 2004 ·Cancer Research ·Saïd Akli,(unknown),Asha S. Multani,Hannah F. Wingate,Sen Pathak,Ning Zhang,Susan L. Tucker,Sandy Chang,Khandan Keyomarsi	117

About Khandan Keyomarsi

Khandan Keyomarsi is a scholar working on Oncology, Cancer Research and Cell Biology, having authored 158 papers that have together received 10.7k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (89 papers), Advanced Breast Cancer Therapies (43 papers) and Microtubule and mitosis dynamics (33 papers). The work is most often cited by research in Oncology (5.5k citations), Cancer Research (2.2k citations) and Cell Biology (1.7k citations). Khandan Keyomarsi has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Arthur B. Pardee, Timothy M. Pawlik, Kelly K. Hunt, Thaddeus W Herliczek, J. Wade Harper, Michael Lowe, Stephen J. Elledge, Saïd Akli, Ruth Sager and Tuyen Bui. Their work appears in journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact